Pol Med Tech plans to launch Japan's first domestic clinical trial of xenotransplantation in early 2028 [1], [2].

The initiative seeks to address critical organ donor shortages by providing a viable treatment alternative for patients suffering from chronic kidney failure [1], [2].

Based in Kawasaki City, Pol Med Tech is a startup spun out of Meiji University [1], [2]. The company is developing a process to transplant genetically modified pig kidneys into human recipients. This approach aims to reduce the risk of organ rejection, a primary hurdle in cross-species transplantation.

The clinical trial is scheduled to begin in early 2028 [2]. According to the project parameters, the candidate patients for these surgeries will fall within the age range of 55 to 65 [3].

By utilizing modified porcine organs, the researchers hope to create a scalable source of kidneys. This would potentially eliminate the years-long wait times currently faced by patients on transplant lists, a systemic issue in the Japanese healthcare system.

The project represents a significant shift in the country's approach to regenerative medicine and surgical innovation [1]. The trial will take place at a designated clinical site in Japan, overseen by the team from the Kawasaki-based startup [1], [2].

“Japan's first domestic clinical trial of xenotransplantation”

The transition to human trials for genetically modified porcine organs marks a pivotal step in solving the global organ shortage. If successful, this trial could validate the safety of xenotransplantation in the Japanese regulatory environment, potentially paving the way for wider adoption of animal-to-human transplants for other failing organs beyond the kidneys.